Copeptin for the prediction of recurrent cerebrovascular events after transient ischemic attack: Results from the CoRisk study

Stroke

Volumn 45, Issue 10, 2014, Pages 2918-2923

  De Marchis, Gian Marco ^a,b,c   Weck, Anja ^a   Audebert, Heinrich ^d   Benik, Steffen ^d   Foerch, Christian ^e   Buhl, Daniela ^a   Schuetz, Philipp ^f   Jung, Simon ^a   Seiler, Marleen ^g   Morgenthaler, Nils G ^d   Mattle, Heinrich P ^a   Mueller, Beat ^f   Christ Crain, Mirjam ^c   Arnold, Marcel ^a   Katan, Mira ^h  

^a UNIVERSITY OF BERN   (Switzerland)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f CANTONAL HOSPITAL AARAU   (Switzerland)

^g THERMO FISHER SCIENTIFIC   (Germany)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

biomarker; copeptin; prediction; stroke; transient ischemic attack

Indexed keywords

COPEPTIN; BIOLOGICAL MARKER; GLYCOPEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CODING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; STROKE PATIENT; SWITZERLAND; TERTIARY CARE CENTER; TRANSIENT ISCHEMIC ATTACK; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; COMPLICATION; IMMUNOASSAY; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; RISK; RISK FACTOR;

AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; GLYCOPEPTIDES; HUMANS; IMMUNOASSAY; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; ROC CURVE;

EID: 84922481303     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005584     Document Type: Article

References (22)

1. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283-292.
2. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al; American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: A scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276-2293.
3. Sanders LM, Srikanth VK, Blacker DJ, Jolley DJ, Cooper KA, Phan TG. Performance of the ABCD2 score for stroke risk post TIA: meta-analysis and probability modeling. Neurology. 2012;79:971-980.
4. Merwick A, Albers GW, Amarenco P, Arsava EM, Ay H, Calvet D, et al. Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack: A multicentre observational study. Lancet Neurol. 2010;9:1060-1069.
5. Katan M, Nigro N, Fluri F, Schuetz P, Morgenthaler NG, Jax F, et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology. 2011;76:563-566.
6. De Marchis GM, Katan M, Weck A, Brekenfeld C, Mattle HP, Buhl D, et al. Copeptin and risk stratification in patients with ischemic stroke and transient ischemic attack: The CoRisk study. Int J Stroke. 2013;8:214-218.
7. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
8. Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charlson Index comorbidity adjustment for ischemic stroke outcome studies. Stroke. 2004;35:1941-1945.
9. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112-119.
10. Vickers AJ, Cronin AM, Begg CB. One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol. 2011;11:13.
11. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172, discussion 207.
12. Katan M, Christ-Crain M. The stress hormone copeptin: A new prognostic biomarker in acute illness. Swiss Med Wkly. 2010;140:w13101.
13. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, et al. Copeptin: A novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009;66:799-808.
14. De Marchis GM, Katan M, Weck A, Fluri F, Foerch C, Findling O, et al. Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology. 2013;80:1278-1286.
15. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American Heart Association. Circulation. 2009;119:2408-2416.
16. Cucchiara BL, Messe SR, Sansing L, MacKenzie L, Taylor RA, Pacelli J, et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke. 2009;40: 2332-2336.
17. Delgado P, Chacón P, Penalba A, Pelegri D, García-Berrocoso T, Giralt D, et al. Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients. Cerebrovasc Dis. 2012;33:150-158.
18. Purroy F, Montaner J, Molina CA, Delgado P, Arenillas JF, Chacon P, et al. C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol Scand. 2007;115:60-66.
19. Corso G, Bottacchi E, Brusa A, Lia C, Cordera S, Giardini G, et al. Blood C-reactive protein concentration with ABCD2 is a better prognostic tool than ABCD2 alone. Cerebrovasc Dis. 2011;32:97-105.
20. Edlow JA, Kim S, Pelletier AJ, Camargo CA Jr. National study on emergency department visits for transient ischemic attack, 1992-2001. Acad Emerg Med. 2006;13:666-672.
21. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al; Oxford Vascular Study. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366:1773-1783.
22. Joshi JK, Ouyang B, Prabhakaran S. Should TIA patients be hospitalized or referred to a same-day clinic?: A decision analysis. Neurology. 2011;77:2082-2088.